RHH646

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Knee OsteoarthritisOsteoarthritis, Knee

Phase 2

Safety and Efficacy of RHH646 for Knee Osteoarthritis

CompletedNCT05816395

Novartis PharmaceuticalsOsteoarthritis, Knee

Start: 2023-05-31End: 2025-02-24Updated: 2026-03-31

A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritis

CompletedCTIS2022-502821-16-00

Novartis Pharma AGKnee Osteoarthritis

Start: 2023-09-01End: 2025-02-11Target: 63Updated: 2025-01-30